Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers

Oncogene

Volumn 30, Issue 42, 2011, Pages 4327-4338

  Wang, Y ^a   Romigh, T ^a   He, X ^a   Tan, M H ^a   Orloff, M S ^a,b   Silverman, R H ^a,b,c   Heston, W D ^a,b,c   Eng, C ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

androgen receptor; breast cancer; Cowden syndrome; prostate cancer; PTEN

Indexed keywords

ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; COWDEN SYNDROME; FEMALE; GENE EXPRESSION; GENE MUTATION; GERM LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN MOTIF; RECEPTOR UPREGULATION; SEX DIFFERENCE; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ANDROGEN; SEX FACTORS;

EID: 80054951975     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.144     Document Type: Article

References (36)

1. Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ. (2003). Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120: 725-731. (Pubitemid 37339680)
2. Agrawal S, Pilarski R, Eng C. (2005). Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Hum Mol Genet 14: 2459-2468. (Pubitemid 41418007)
3. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY et al. (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277: 965-968. (Pubitemid 27366683)
4. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA et al. (2007). Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 13: 3860-3867. (Pubitemid 47037592)
5. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ et al. (1995). Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 52: 459-467.
6. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L et al. (1997). Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90: 569-580. (Pubitemid 27347246)
7. Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA, Baniahmad A. (2002). The amino terminus of the human AR is target for corepressor action and antihormone agonism. Mol Endocrinol 16: 661-673. (Pubitemid 34297738)
8. Eng C. (2003). PTEN: one gene, many syndromes. Hum Mutat 22: 183-198. (Pubitemid 37071635)
9. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ et al. (2005). Signal transduction pathways in androgen-dependent and-independent prostate cancer cell proliferation. Endocr Relat Cancer 12: 119-134. (Pubitemid 40477093)
10. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E et al. (2005). The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 280: 6511-6519. (Pubitemid 40341200)
11. Ihaka S, Gentleman R. (1996). R: a language for data analysis and graphics. J Comput Graph Stat 5: 299-314.
12. Li H, Gomes PJ, Chen JD. (1997). RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94: 8479-8484. (Pubitemid 27335064)
13. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z et al. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64-67. (Pubitemid 27198157)
14. Lin HK, Hu YC, Lee DK, Chang C. (2004). Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 18: 2409-2423. (Pubitemid 39335977)
15. Manin M, Baron S, Goossens K, Beaudoin C, Jean C, Veyssiere G et al. (2002). Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 366: 729-736.
16. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z et al. (1998). Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7: 507-515. (Pubitemid 28120643)
17. Mikhailova M, Wang Y, Bedolla R, Lu XH, Kreisberg JI, Ghosh PM. (2008). AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer. Adv Exp Med Biol 617: 397-405.
18. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA et al. (2000). Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924-930.
19. Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M. (2003). The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 31: 169-183. (Pubitemid 37063087)
20. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H et al. (2008). Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13: 431-435.
21. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL et al. (1999). Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155: 1253-1260. (Pubitemid 29488932)
22. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A et al. (2009). PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218: 505-513.
23. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y et al. (2001). Regulation of PTEN transcription by p53. Mol Cell 8: 317-325. (Pubitemid 32831549)
24. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39. (Pubitemid 28458022)
25. Tang Y, Eng C. (2006). PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res 66: 736-742. (Pubitemid 43165936)
26. Teresi RE, Planchon SM, Waite KA, Eng C. (2008). Regulation of the PTEN promoter by statins and SREBP. Hum Mol Genet 17: 919-928. (Pubitemid 351426026)
27. Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C. (2007). Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet 81: 756-767. (Pubitemid 47596543)
28. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C et al. (1995). in vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406.
29. Wang SI, Parsons R, Ittmann M. (1998). Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarci-nomas. Clin Cancer Res 4: 811-815. (Pubitemid 28193582)
30. Wang Y, Kreisberg JI, Ghosh PM. (2007). Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 7: 591-604. (Pubitemid 47358145)
31. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. (2008). Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 27: 7106-7117.
32. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH et al. (2000). HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60: 6841-6845. (Pubitemid 32059149)
33. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL et al. (1998). Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95: 5246-5250. (Pubitemid 28208583)
34. Zbuk KM, Eng C. (2007). Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7: 35-45. (Pubitemid 46020845)
35. Zhou XP, Marsh DJ, Morrison CD, Chaudhury AR, Maxwell M, Reifenberger G et al. (2003a). Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 73: 1191-1198. (Pubitemid 37414231)
36. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C et al. (2003b). Germline PTEN promoter mutations and deletions in Cowden/Bannayan- Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 73: 404-411. (Pubitemid 36921003)